The companies will conduct a joint technical assessment using Framatome's proprietary isotope production technology, already operational at Canada's Bruce Power nuclear facility.
"We see commercial nuclear reactors increasingly supporting research reactors in the production of oncology radioisotopes," stated Francois Gauche, Head of Framatome Healthcare. "This collaboration is aimed at ensuring a stable supply of Lutetium-177 worldwide."
This partnership mirrors a recent agreement between Framatome and Nuclearelectrica in Romania to assess the potential of the CANDU reactor at Wolsong for future Korean production of essential radioisotopes.
"KHNP is committed to advancing modern nuclear medicine treatments in South Korea, aligning with our ongoing efforts towards stable energy supply and carbon neutrality," noted Chang Hee-Seung, Executive Vice-President at KHNP.
Catherine Cornand, Senior Executive Vice President at Framatome, highlighted the long-standing partnership with KHNP, supporting the operation of the Hanul 1 and 2 plants, "We are delighted to further our collaboration through this innovative initiative at the Wolsong plant."
Lutetium-177, used in targeted therapy for prostate cancer and other cancer treatments, destroys cancer cells while sparing healthy tissue. Framatome's technology facilitated the first large-scale Lutetium-177 production in a power reactor in October 2022.
Framatome Healthcare continues to develop healthcare products and services, supporting the entire value chain of radiopharmaceuticals used in diagnostic imaging and therapy. They also provide materials for surgical implants and advanced sterilization solutions for medical materials, contributing to ongoing cancer treatment advancements.
Related Links
Framatome
Nuclear Power News - Nuclear Science, Nuclear Technology
Powering The World in the 21st Century at Energy-Daily.com
| Subscribe Free To Our Daily Newsletters |
| Subscribe Free To Our Daily Newsletters |
